209 related articles for article (PubMed ID: 9892384)
41. [Erythropoietin treatment in Piedmont and Valle d'Aosta].
Imarisio P; Biamino E; Bongiorno P; Caligaris F; Demicheli G; Montalcini G; Arnaud A
Minerva Urol Nefrol; 1991; 43(3):143-5. PubMed ID: 1817336
[TBL] [Abstract][Full Text] [Related]
42. Erythropoietin use in peritoneal dialysis patients.
Zimmerman SW; Johnson CA
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):38-41. PubMed ID: 1928078
[TBL] [Abstract][Full Text] [Related]
43. Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model.
Messana JM; Chuang CC; Turenne M; Wheeler J; Turner J; Sleeman K; Tedeschi P; Hirth R
Am J Kidney Dis; 2009 Mar; 53(3):503-12. PubMed ID: 19185402
[TBL] [Abstract][Full Text] [Related]
44. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
45. Weekly subcutaneous erythropoietin maintains hematocrit in chronic hemodialysis patients.
Parker KP; Sands JM
J Am Soc Nephrol; 1993 Apr; 3(10):1717-8. PubMed ID: 8318688
[No Abstract] [Full Text] [Related]
46. [Human recombinant erythropoietin in the treatment of anemia in patients on long-term hemodialysis].
Boratyńska M; Szewczyk Z; Szepietowski T; Czyz W; Cybulski K; Bogucki J; Szczepański J
Przegl Lek; 1990; 47(11):741-5. PubMed ID: 2098840
[TBL] [Abstract][Full Text] [Related]
47. Should the hematocrit be normalized in dialysis and in pre-ESRD patients?
Macdougall IC
Blood Purif; 2001; 19(2):157-67. PubMed ID: 11150803
[No Abstract] [Full Text] [Related]
48. Recombinant human erythropoietin correction of anemia. Dialysis efficiency, waste retention, and chronic dose variables.
Paganini EP; Abdulhadi MH; Garcia J; Magnusson MO
ASAIO Trans; 1989; 35(3):513-5. PubMed ID: 2688718
[TBL] [Abstract][Full Text] [Related]
49. [Erythropoietin, blood viscosity and hypertension in chronic kidney failure].
Schaefer RM; Heidland A
Dtsch Med Wochenschr; 1989 Jun; 114(26):1046-9. PubMed ID: 2661190
[No Abstract] [Full Text] [Related]
50. Use of low-dose subcutaneous recombinant human erythropoietin in end-stage renal disease: experience with children receiving continuous cycling peritoneal dialysis.
Ongkingco JR; Ruley EJ; Turner ME
Am J Kidney Dis; 1991 Oct; 18(4):446-50. PubMed ID: 1928063
[TBL] [Abstract][Full Text] [Related]
51. [Use of human recombinant erythropoietin (rHuEPO) for treatment of anemia in patients with chronic kidney failure who don't require additional dialysis therapy].
Wiecek A
Przegl Lek; 1995; 52(3):93-4. PubMed ID: 7644683
[No Abstract] [Full Text] [Related]
52. How to design an anemia management protocol.
Senger JM; Trenkle JA; St John WD
ANNA J; 1998 Apr; 25(2):235-40. PubMed ID: 9801503
[TBL] [Abstract][Full Text] [Related]
53. Monitoring erythropoietin therapy for anaemia of chronic renal failure by serum erythropoietin assays.
Marsden JT; Sherwood RA; Hillis A; Peters TJ
Ann Clin Biochem; 1993 Mar; 30 ( Pt 2)():205-6. PubMed ID: 8466156
[No Abstract] [Full Text] [Related]
54. Target haematocrit during erythropoietin treatment in dialysis patients. Which value is 'true-functional haematocrit'?
Vlassopoulos D; Sonikian M; Dardioti V; Hadjiconstantinou V
Nephrol Dial Transplant; 1999 May; 14(5):1340-1. PubMed ID: 10344405
[No Abstract] [Full Text] [Related]
55. Optimizing dose and mode of renal replacement therapy in anaemia management.
Locatelli F
Nephrol Dial Transplant; 2002; 17 Suppl 5():60-5. PubMed ID: 12091610
[TBL] [Abstract][Full Text] [Related]
56. [Use of erythropoietin in patients with chronic renal insufficiency and in hemodialysis].
Cuero CJ; Pérez Guardia E; de Rivera C
Rev Med Panama; 1996; 21(1-2):55-9. PubMed ID: 8966240
[TBL] [Abstract][Full Text] [Related]
57. Recombinant erythropoietin for the anemia of chronic renal failure.
Ahmad R; Hand M
N Engl J Med; 1987 Jul; 317(3):169-70. PubMed ID: 3600706
[No Abstract] [Full Text] [Related]
58. Parathyroidectomy and response to erythropoietin therapy in anaemic patients with chronic renal failure.
Mandolfo S; Malberti F; Farina M; Villa G; Scanziani R; Surian M; Imbasciati E
Nephrol Dial Transplant; 1998 Oct; 13(10):2708-9. PubMed ID: 9794600
[No Abstract] [Full Text] [Related]
59. Hematocrit above 30% in continuous ambulatory peritoneal dialysis patients treated with erythropoietin is harmful.
Junor BJ
Perit Dial Int; 1993; 13 Suppl 2():S535-7. PubMed ID: 8399658
[No Abstract] [Full Text] [Related]
60. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.
Acharya VN; Sinha DK; Almeida AF; Pathare AV
J Assoc Physicians India; 1995 Aug; 43(8):539-42. PubMed ID: 8772973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
